Filters

Clear all

Expert Opinion

Plain Language Summary

Expert Review

Text Availability

Abstract

145

Full text

119

Free full text

Publication Types

Journal Article

148

Research Support, Non-U.S. Gov't

Clinical Trial

Review

Comparative Study

Randomized Controlled Trial

Multicenter Study

Meta-Analysis

Systematic Review

Clinical Trial, Phase II

Observational Study

Controlled Clinical Trial

Clinical Trial, Phase III

Research Support, N.I.H., Extramural

Comment

Case Reports

Clinical Trial, Phase I

Letter

Evaluation Study

Clinical Trial, Phase IV

Network Meta-Analysis

Clinical Trial Protocol

Publication Year

From

Quick links

Individual year

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2006

2005

2004

2003

2002

2001

2000

Sort by:

selected

Print page

Email selected articles

Favourite selected articles

Create a NED Search Alert for this search

Save this search

Advanced Search

Run an advanced search

Results for
""Deferiprone""[mesh_terms]

150 Results

Searching titles within these results

Idiosyncratic drug-induced agranulocytosis: the paradigm of deferiprone.

Helen A Papadaki, Charalampos Pontikoglou

Hemoglobin 2011;34(3):291-304

Full Text

Abstract

Efficacy of the iron-chelating agent, deferiprone, in patients with Parkinson's disease: A systematic review and meta-analysis.

Heba Aboeldahab, Matthew J Barrett, Leslie J Cloud, Nivin Cadri, Shirin Cadri, Yasmin Negida, Youmna E Zain, Nafisa M Hassan, Brian Berman, Ahmed Negida

CNS neuroscience & therapeutics 2024;30(2):e14607

Free Full Text

Abstract

Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1).

Y Rombos, R Tzanetea, K Konstantopoulos, S Simitzis, C Zervas, P Kyriaki, M Kavouklis, A Aessopos, N Sakellaropoulos, M Karagiorga, V Kalotychou, D Loukopoulos

Haematologica 2000;85(2):115-7

Full Text

Abstract

Decreasing iron neurotoxicity in pantothenate kinase-associated neurodegeneration.

Ashley I Bush, Scott Ayton

The Lancet. Neurology 2020;18(7):616-617

Full Text

Deferiprone and Iron-Maltol: Forty Years since Their Discovery and Insights into Their Drug Design, Development, Clinical Use and Future Prospects.

George J Kontoghiorghes

International journal of molecular sciences 2023;24(5):4970

Free Full Text

Abstract

Protective Effects of Curcumin against Iron-induced Toxicity.

Nastaran Moinipour, Mahdi Barati, Amirhossein Sahebkar, Milad Iranshahy, Abolfazl Shakeri

Current pharmaceutical biotechnology 2022;23(8):1020-1027

Full Text

Abstract

Deferiprone for the treatment of transfusional iron overload in thalassemia.

Janet L Kwiatkowski, Ami Belmont

Expert review of hematology 2017;10(6):493-503

Full Text

Abstract

Iron Chelation Therapy.

Irene Motta, Maria Domenica Cappellini, Natalia Scaramellini, Simona Leoni

Advances in experimental medicine and biology 2025;1480():361-370

Full Text

Abstract

Drug reduces excess iron in ultra-rare neurodegenerative disease.

Sarah Lemprière

Nature reviews. Neurology 2020;15(9):492-493

Full Text

Design and synthesis of novel pegylated iron chelators with decreased metabolic rate.

Robert C Hider, Vincenzo Abbate, Sukhvinder S Bansal, Yongmin Ma, Xiaole Kong, Xingyuan Zhang, Junpei Li, Zidong Lu

Future medicinal chemistry 2016;7(18):2439-49

Full Text

Abstract

LPI-labile plasma iron in iron overload.

Z Ioav Cabantchik, William Breuer, G Zanninelli, P Cianciulli

Best practice & research. Clinical haematology 2005;18(2):277-87

Full Text

Abstract

Molecular factors and mechanisms affecting iron and other metal excretion or absorption in health and disease: the role of natural and synthetic chelators.

Annita Kolnagou, George J Kontoghiorghes

Current medicinal chemistry 2006;12(23):2695-709

Full Text

Abstract

Deferiprone-related arthropathy of the knee in a thalassemic patient: report of a case and review of the literature.

Efthimia Vlachaki, Konstantinos Tselios, Vasilios Perifanis, Ioanna Tsatra, Ioannis Tsayas

Clinical rheumatology 2009;27(11):1459-61

Full Text

Abstract

Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis.

Dudley J Pennell, Vasili Berdoukas, Markissia Karagiorga, Vasili Ladis, Antonio Piga, Athanassios Aessopos, Efstathios D Gotsis, Mark A Tanner, Gill C Smith, Mark A Westwood, Beatrix Wonke, Renzo Galanello

Blood 2006;107(9):3738-44

Free Full Text

Abstract

Iron chelation therapy.

Isabella Capodanno, Gianfranco Filippelli, Carlo Bova, Virginia Olivito, Eugenio Lucia, Francesco Mendicino, Enrica Antonia Martino, Antonella Bruzzese, Antonino Neri, Ernesto Vigna, Massimo Gentile, Fortunato Morabito

European journal of haematology 2023;110(5):490-497

Full Text

Abstract

Results: 1 – 15 / 150

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Deferiprone""[mesh_terms]

Idiosyncratic drug-induced agranulocytosis: the paradigm of deferiprone.

Efficacy of the iron-chelating agent, deferiprone, in patients with Parkinson's disease: A systematic review and meta-analysis.

Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1).

Decreasing iron neurotoxicity in pantothenate kinase-associated neurodegeneration.

Deferiprone and Iron-Maltol: Forty Years since Their Discovery and Insights into Their Drug Design, Development, Clinical Use and Future Prospects.

Protective Effects of Curcumin against Iron-induced Toxicity.

Deferiprone for the treatment of transfusional iron overload in thalassemia.

Iron Chelation Therapy.

Drug reduces excess iron in ultra-rare neurodegenerative disease.

Design and synthesis of novel pegylated iron chelators with decreased metabolic rate.

LPI-labile plasma iron in iron overload.

Molecular factors and mechanisms affecting iron and other metal excretion or absorption in health and disease: the role of natural and synthetic chelators.

Deferiprone-related arthropathy of the knee in a thalassemic patient: report of a case and review of the literature.

Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis.

Iron chelation therapy.

Results for
""Deferiprone""[mesh_terms]